Transition Bio Analysis: $77M Raised
What is Transition Bio?
Condensate drug discovery platform leveraging microfluidics
HQ Country
Cambridge, United States
Employees
11-50
Founded
2020
HQ State/Province
Massachusetts
Funding Category
Series A
HQ Full Address
Cambridge, Massachusetts, United States
Product Features & Capabilities
- Condensate drug discovery platform
- Droplet microfluidics technology
- Cellular imaging solutions
- Machine learning optimization for drug discovery
Other Considerations
Closed $50 million Series A financing; Presented research at AACR-NCI-EORTC 2025; Leadership team includes experienced executives from biotech
